

Patrys' Research Recognised by Leading European Oncology Society

- **Awarded first place poster prize for outstanding preclinical multiple myeloma research**
- **Peer-reviewed work recognised by German Society for Haematology & Oncology**
- **Phase I/IIa clinical trial in multiple myeloma based on this outstanding research**

Melbourne, Australia; 25 October, 2012: Patrys Limited (ASX: PAB; "the Company"), a clinical stage biopharmaceutical company, is pleased to announce the presentation of new scientific data regarding its lead anti-cancer candidate PAT-SM6.

Patrys' research team has won first prize for their poster at this year's prestigious German Society for Haematology and Oncology (DGHO) Congress in Stuttgart, Germany. The poster titled "PAT-SM6 – a novel antibody targeting multiple myeloma" received the award for the best poster presentation in the section "multiple myeloma" among other prominent works from the members of the German, Austrian and Swiss Societies for Haematology and Oncology. The senior author of this paper was Dr. Leo Rasche from the Dept. Haematology and Oncology, University of Würzburg.

This work is the result of a long standing collaboration between leading multiple myeloma experts from the Dept. of Haematology and Oncology, University of Würzburg Germany and Patrys. The preclinical data presented in the poster form the basis for the phase I/IIa dose escalating study in patients with relapsed multiple myeloma that is to commence in the fourth quarter of 2012 at the University Hospital Würzburg, Germany.

Patrys CEO Dr. Marie Roskrow, commented: "We are delighted that our preclinical work on multiple myeloma has been appreciated by an expert audience at the DGHO Conference this year. The multiple myeloma experts in Würzburg are very excited to be working with Patrys and they are looking forward to initiating the PAT-SM6 trial very soon."

Ends -

For further information, please contact:

Patrys Limited:

Dr. Marie Roskrow
Chief Executive Officer
P: +61 3 9670 3273
info@patrys.com

Patrys IR:

Rebecca Wilson
Buchan Consulting
P: 0417 382 391
rwilson@buchanwe.com.au

Patrys Media:

Shevaun Cooper
Buchan Consulting
P: +61 3 9866 4722
scooper@buchanwe.com.au

About Patrys Limited:

Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of natural human antibody therapies for cancer. More information can be found at www.patrys.com.

About PAT-SM6:

The natural human antibody PAT-SM6 has been shown to have potent anti-cancer properties in a large number of laboratory and animal studies. More specifically, Patrys has now screened PAT-SM6 against more than 200 tumours from individual patients with various cancers, and the product binds to over 90% of the tumours screened regardless of cancer type or patient age, gender or disease stage. With respect to multiple myeloma PAT-SM6 has shown particularly strong promise. Patrys has filed patent applications to cover the PAT-SM6 antibody molecule, disease target, and the mechanism of action. Patrys has successfully completed a Phase I clinical trial to evaluate PAT-SM6 as a therapy for melanoma.



About Multiple Myeloma:

Multiple myeloma is a type of bone marrow cancer arising from plasma cells, and new therapies are desperately needed to treat patients who become resistant to established chemotherapeutics. There is an estimated 200,000 cases worldwide and the incidence is increasing. The five-year survival of patients is approximately 40% (at 10 years ~20%). Despite new marketed therapies, multiple myeloma remains largely incurable and fatal. The multiple myeloma market is dominated by three major products: Revlimid, Velcade and Thalidomide with combined net sales greater than US\$3 Billion in 2010.